Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) GS-US-384-1944
Description The study visits will be in downtown Buffalo.

If you are interested in this study, please contact the study coordinator below.
Objective The purpose of this study is to see if selonsertib is safe, well tolerated, and whether it can reduce fibrosis and associated complications in subjects with cirrhosis fibrosis due to NASH.

Keywords: NASH, Non-alcoholic Steatohepatitis, liver, fibrosis, cirrhosis
Principal Investigator TALAL, ANDREW
Age Group Adult
Drugs Involved
Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT03053063/
Status Open
Key Eligibility Nonalcoholic Steatohepatitis (NASH)
Liver Cirrhosis
Disease Group Digestive System; Liver Diseases
Treatment selonsertib (SEL; GS-4997)
Contact RICHARD REJMAN
716-878-3320
rmrejman@buffalo.edu